August O O O O
30th O O O O
2023 O O O O
According O O O O
to O O O O
a O O O O
recent O O O O
Morbidity O O O O
and O O O O
Mortality O O O O
Weekly O O O O
Report, O O O O
the Reason 5 O O
original Reason 5 O O
COVID-19 Reason 5 O O
monovalent Reason 5 O O
and Reason 5 O O
bivalent Reason 5 O O
vaccines Reason 5 O O
helped Reason 5 O O
reduce Reason 5 O O
emergency Reason 5 O O
department Reason 5 O O
or Reason 5 O O
urgent Reason 5 O O
care Reason 5 O O
encounters Reason 5 O O
for Reason 5 O O
children Reason 5 O O
aged Reason 5 O O
6 Reason 5 O O
months Reason 5 O O
to Reason 5 O O
5 Reason 5 O O
years. Reason 5 O O
July O O O O
31st O O O O
2023 O O O O
[FDA O O O O
approves O O O O
20-valent O O O O
pneumococcal O O O O
conjugate O O O O
vaccine O O O O
for O O O O
infants O O O O
6 O O O O
weeks O O O O
and O O O O
older](/view/fda-approves-20-valent-pneumococcal-conjugate-vaccine-for-infants-6-weeks-and-older) O O O O
According O O O O
to O O O O
Pfizer, O O O O
the Reason 5 O O
company's Reason 5 O O
pneumococcal Reason 5 O O
conjugate Reason 5 O O
vaccine Reason 5 O O
Prevnar Reason 5 O O
20 Reason 5 O O
has Reason 5 O O
been Reason 5 O O
approved Reason 5 O O
by Reason 5 O O
the Reason 5 O O
FDA Reason 5 O O
to Reason 5 O O
treat Reason 5 O O
infants Reason 5 O O
and Reason 5 O O
children Reason 5 O O
aged Reason 5 O O
6 Reason 5 O O
weeks Reason 5 O O
to Reason 5 O O
17 Reason 5 O O
years Reason 5 O O
for Reason 5 O O
the Reason 5 O O
prevention Reason 5 O O
of Reason 5 O O
invasive Reason 5 O O
pneumococcal Reason 5 O O
disease Reason 5 O O
(IPD). Reason 5 O O
[Half O O O O
of O O O O
meningococcal O O O O
vaccination O O O O
appointments O O O O
delayed O O O O
or O O O O
canceled O O O O
during O O O O
COVID-19 O O O O
pandemic](/view/half-of-meningococcal-vaccination-appointments-delayed-or-canceled-during-covid-19-pandemic) O O O O
A O O O O
multi-country O O O O
survey O O O O
revealed O O O O
50% Reason 1 O O
of Reason 1 O O
meningitis Reason 1 O O
vaccination Reason 1 O O
appointments Reason 1 O O
were Reason 1 O O
delayed Reason 1 O O
or Reason 1 O O
canceled Reason 1 O O
amid Reason 1 O O
the Reason 1 O O
COVID-19 Reason 1 O O
pandemic, Reason 1 O O
highlighting Reason 1 O O
the Reason 1 O O
need Reason 1 O O
for Reason 1 O O
"urgent Reason 1 O O
action" Reason 1 O O
to Reason 1 O O
maintain Reason 1 O O
routine Reason 1 O O
vaccination Reason 1 O O
levels Reason 1 O O
among Reason 1 O O
children, Reason 1 O O
according Reason 1 O O
to Reason 1 O O
survey Reason 1 O O
authors. Reason 1 O O
[FDA O O O O
authorizes O O O O
bivalent O O O O
Pfizer-BioNTech O O O O
COVID-19 O O O O
vaccine O O O O
as O O O O
booster O O O O
dose O O O O
for O O O O
children O O O O
6 O O O O
months O O O O
through O O O O
4 O O O O
years O O O O
of O O O O
age](/view/fda-authorizes-bivalent-pfizer-biontech-covid-19-vaccine-as-booster-dose-for-children-6-months-through-4-years-of-age-) O O O O
A Reason 5 O O
new Reason 5 O O
booster Reason 5 O O
shot Reason 5 O O
of Reason 5 O O
the Reason 5 O O
Pfizer-BioNTech Reason 5 O O
COVID-19 Reason 5 O O
vaccine Reason 5 O O
is Reason 5 O O
now Reason 5 O O
available Reason 5 O O
for Reason 5 O O
young Reason 5 O O
children Reason 5 O O
to Reason 5 O O
help Reason 5 O O
protect Reason 5 O O
this Reason 5 O O
population Reason 5 O O
against Reason 5 O O
serious Reason 5 O O
COVID-19 Reason 5 O O
effects. Reason 5 O O
[Effectiveness O O O O
of O O O O
monovalent O O O O
mRNA O O O O
vaccines O O O O
against O O O O
COVID-19 O O O O
in O O O O
young O O O O
children](/view/effectiveness-of-monovalent-mrna-vaccines-against-covid-19-in-young-children) O O O O
In O O O O
a O O O O
recent O O O O
report O O O O
from O O O O
the O O O O
CDC, O O O O
monovalent Reason 5 O O
vaccines Reason 5 O O
from Reason 5 O O
Moderna Reason 5 O O
and Reason 5 O O
Pfizer Reason 5 O O
have Reason 5 O O
shown Reason 5 O O
vaccine Reason 5 O O
effectiveness Reason 5 O O
in Reason 5 O O
children Reason 5 O O
aged Reason 5 O O
3 Reason 5 O O
to Reason 5 O O
5 Reason 5 O O
years Reason 5 O O
in Reason 5 O O
at Reason 5 O O
least Reason 5 O O
the Reason 5 O O
first Reason 5 O O
4 Reason 5 O O
months Reason 5 O O
after Reason 5 O O
vaccination. Reason 5 O O
[Bivalent O O O O
COVID-19 O O O O
booster O O O O
safety O O O O
profile O O O O
consistent O O O O
with O O O O
monovalent O O O O
vaccine](/view/bivalent-covid-19-booster-safety-profile-consistent-with-monovalent-vaccine) O O O O
The O O O O
Centers O O O O
for O O O O
Disease O O O O
Control O O O O
and O O O O
Prevention O O O O
has O O O O
provided O O O O
an Reason 4 O O
updated Reason 4 O O
safety Reason 4 O O
profile Reason 4 O O
on Reason 4 O O
the Reason 4 O O
bivalent Reason 4 O O
COVID-19 Reason 4 O O
booster Reason 4 O O
vaccine Reason 4 O O
in Reason 4 O O
children Reason 4 O O
aged Reason 4 O O
5 Reason 4 O O
to Reason 4 O O
11 Reason 4 O O
years, Reason 4 O O
showing Reason 4 O O
similar Reason 4 O O
adverse Reason 4 O O
events Reason 4 O O
to Reason 4 O O
the Reason 4 O O
monovalent Reason 4 O O
vaccine. Reason 4 O O
[COVID-19 O O O O
vaccine O O O O
safe O O O O
90 O O O O
days O O O O
after O O O O
MIS-C O O O O
diagnosis O O O O
](/view/covid-19-vaccine-safe-90-days-after-mis-c-diagnosis) O O O O
Patients O O O O
with O O O O
a O O O O
history O O O O
of O O O O
multisystem O O O O
inflammatory O O O O
syndrome O O O O
in O O O O
children O O O O
(MIS-C) O O O O
completed O O O O
a O O O O
questionnaire O O O O
about O O O O
adverse O O O O
reactions O O O O
following O O O O
COVID-19 O O O O
vaccination, O O O O
and Reason 5 O O
no Reason 5 O O
serious Reason 5 O O
adverse Reason 5 O O
events Reason 5 O O
were Reason 5 O O
recorded. Reason 5 O O
[Effectiveness O O O O
of O O O O
cell-based O O O O
vaccines O O O O
against O O O O
influenza](/view/effectiveness-of-cell-based-vaccines-against-influenza) O O O O
Deborah O O O O
Molrine, O O O O
MD, O O O O
discusses O O O O
CSL O O O O
Seqirus' O O O O
cell-based O O O O
quadrivalent O O O O
seasonal O O O O
influenza O O O O
vaccine, O O O O
along O O O O
with O O O O
the Reason 5 O O
effectiveness Reason 5 O O
of Reason 5 O O
cell-based Reason 5 O O
vaccines Reason 5 O O
in Reason 5 O O
children. Reason 5 O O
[FDA O O O O
grants O O O O
emergency O O O O
use O O O O
authorization O O O O
to O O O O
Moderna's O O O O
COVID-19 O O O O
booster O O O O
in O O O O
pediatric O O O O
patients](/view/fda-grants-emergency-use-authorization-to-moderna-s-covid-19-booster-in-pediatric-patients) O O O O
Moderna Reason 5 O O
has Reason 5 O O
announced Reason 5 O O
that Reason 5 O O
their Reason 5 O O
latest Reason 5 O O
BA.4/BA.5 Reason 5 O O
Omicron-targeting Reason 5 O O
bivalent Reason 5 O O
COVID-19 Reason 5 O O
booster Reason 5 O O
vaccine, Reason 5 O O
mRNA-1273.222, Reason 5 O O
has Reason 5 O O
been Reason 5 O O
granted Reason 5 O O
Emergency Reason 5 O O
Use Reason 5 O O
Authorization Reason 5 O O
by Reason 5 O O
the Reason 5 O O
US Reason 5 O O
Food Reason 5 O O
and Reason 5 O O
Drug Reason 5 O O
Administration. Reason 5 O O
